Subcutaneous insulin lispro vs intravenous regular insulin
- Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 90 participantsVery low
The review found no eligible studies for this question.
Subcutaneous insulin aspart showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days compared with intravenous regular insulin (low certainty).
It is very uncertain whether insulin analogues changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with biphasic insulin (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).
It is very uncertain whether insulin analogues changes all‐cause mortality compared with biphasic insulin (very low certainty).
The review found no eligible studies for this question.
Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.